Skip to main navigation Skip to search Skip to main content

Durvalumab _ Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

  • Luis Paz-Ares
  • , Marina Chiara Garassino
  • , Yuanbin Chen
  • , Niels Reinmuth
  • , Katsuyuki Hotta
  • , Artem Poltoratskiy
  • , Dmytro Trukhin
  • , Maximilian J. Hochmair
  • , Mustafa Özgüroǧlu
  • , Jun Ho Ji
  • , Galina Statsenko
  • , Nikolay Conev
  • , Igor Bondarenko
  • , Libor Havel
  • , György Losonczy
  • , Mingchao Xie
  • , Zhongwu Lai
  • , Nadia Godin-Heymann
  • , Helen Mann
  • , Haiyi Jiang
  • Yashaswi Shrestha, Jonathan W. Goldman
  • Complutense University
  • IRCCS Fondazione Istituto Nazionale per lo studio e la cura dei tumori - Milano
  • The University of Chicago
  • Cancer and Hematology Centers of Western Michigan
  • Member of the German Center for Lung Research (DZL)
  • Okayama University
  • Russian Ministry of Health
  • Odessa Regional Oncological Dispensary
  • Klinik Floridsdorf
  • Istanbul University - Cerrahpaşa
  • Samsung Changwon Hospital
  • Omsk Regional Cancer Center
  • Clinic of Medical Oncology
  • Zaporizhia Medical Academy of Post-Gradate Education Ministry of Health of Ukraine
  • Charles University
  • Semmelweis University
  • AstraZeneca
  • Astra- Zeneca
  • University of California at Los Angeles

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Durvalumab _ Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry

Agricultural and Biological Sciences